



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

July 9, 2015

Via E-mail

Sunil Bhonsle  
President  
Titan Pharmaceuticals, Inc.  
400 Oyster Point Boulevard, Suite 505  
South San Francisco, California 94080

**Re: Titan Pharmaceuticals, Inc.  
Preliminary Proxy Statement on Schedule 14A  
Filed June 26, 2015  
File No. 000-27436**

Dear Mr. Bhonsle:

We have completed our review of your filing. We remind you that our comment or changes to disclosure in response to our comment does not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Greenspan for

Jeffrey P. Riedler  
Assistant Director